查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1855544

吸入式一氧化氮市场按产品、应用、最终用户和分销管道划分－2025-2032年全球预测

Inhaled Nitric Oxide Market by Product, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，吸入式一氧化氮市场规模将达到 13.1361 亿美元，复合年增长率为 6.04%。

关键市场统计数据
基准年 2024 8.2109亿美元
预计年份：2025年 8.7137亿美元
预测年份 2032 13.1361亿美元
复合年增长率 (%) 6.04%

全面介绍吸入一氧化氮的临床作用、输送方式及其在从新生儿到成人的肺部护理中的策略意义。

吸入一氧化氮（iNO）已从一种小众疗法发展成为多种急性慢性肺部疾病的重要辅助治疗。一氧化氮作为一种选择性肺血管扩张剂，在需要快速调节肺血管阻力和氧合的情况下发挥重要作用，这为其临床效用提供了有力支持。临床医生和医疗系统领导者日益将iNO视为在常规治疗方法不足时提供标靶呼吸支持的关键工具，这引起了医院管理者、呼吸治疗团队和采购部门的广泛关注。

随着新生儿加护治疗、成人重症加护和专科肺科计画之间的诊疗路径日益融合，相关人员都在寻求更深入地了解产品形式、输送平台和分销管道如何影响临床工作流程和营运准备。本报告重点在于气瓶、产生器和罐式气瓶等不同产品形式的差异，以及这些输送方式如何与特定应用通讯协定相互作用，涵盖从新生儿肺动脉高压到成人急性呼吸窘迫症候群的治疗。透过整合临床、物流和支付方的观点，本报告着重阐述了产品的临床原理、实际应用场景以及决策者在将吸入一氧化氮（iNO）纳入诊疗路径时必须考虑的策略因素。

技术进步、监管调整和供应弹性措施如何重塑吸入一氧化氮的临床应用和筹资策略

近年来，吸入一氧化氮领域发生了许多变革性变化，重塑了临床应用和供应链动态。输送技术的进步催生了更紧凑、整合化的发生器和携带式解决方案，缩短了床边设置时间，并扩大了其在门诊和居家医疗环境中的适用范围。与技术进步同步，临床通讯协定的扩展以及吸入一氧化氮在难治性低氧血症和肺动脉高压治疗中的广泛应用，促使医疗机构的采购重点转向可靠的按需供应模式。

监管和报销趋势也在影响临床决策，促使医疗机构重新评估治疗流程，并增加对员工培训和基础设施的投资。临床团队与分销合作伙伴之间的策略伙伴关係已成为缓解供应不稳定和确保医疗服务连续性的关键机制。此外，对互通性和数据整合的日益重视促使製造商将使用情况追踪功能整合到设备中，以支援品质保证，并促进与支付方和医疗系统就合理使用和通讯协定进行讨论。总而言之，这些变化正在形成一个临床疗效、交付灵活性和供应韧性日益相互依存的局面。

评估2025年美国关税调整对吸入式一氧化氮的营运和采购影响，这些调整促使供应商转向供应链弹性计画。

美国2025年实施的关税调整对吸入式一氧化氮产品及相关硬体的采购、定价结构和供应链规划产生了复杂的连锁反应。进口关税和关税调整推高了某些进口零件和成品的成本，迫使製造商和经销商重新评估其筹资策略和库存状况。这种环境加速了关键製造流程的近岸外包，并促使企业重新谈判供应合同，以应对到岸成本和前置作业时间的变化。

医院和医疗系统采取的应对措施是加强与分销合作伙伴的协作，以确保签订更长期的供应协议和紧急条款。临床团队将供应风险评估纳入治疗方法选择的讨论中，优先考虑能够可靠地适应不断变化的商业环境的设备和产品。同时，采购负责人考虑了气瓶、发生器和储槽等方案的总拥有成本，并考虑到库存持有量、运输限制和培训需求。这些策略调整降低了因个别关税波动而导致的供应中断风险，提高了医疗服务的连续性，并凸显了灵活合约、多供应商采购和库存可视性在维持关键吸入一氧化氮疗法供应方面的重要性。

基于细分市场的详细洞察，解释了产品形态、临床用途、最终用户环境和分销管道如何决定采购和临床部署选择。

细分市场分析揭示了产品选择、临床应用、终端用户偏好和通路的关键差异，这些差异为产品推广和营运规划提供了基础。按产品类型划分，本文探讨了气瓶、产生器和储罐，每种产品在储存、床边工作流程和维护要求方面都有其独特的影响。气瓶支援快速部署和小型医疗机构，发生器可为大型医疗机构提供整合剂量控制，而储槽则非常适合服务多家医疗机构的集中式给药模式。按应用领域划分，本文探讨了成人肺动脉高压、急性呼吸窘迫症候群（ARDS）和新生儿肺动脉高压。成人肺动脉高压依其不同的诊断路径、併发症情况和长期管理策略，分为特发性肺动脉高压和续发性肺动脉高压。在ARDS领域，本文进一步探讨了体外膜氧气疗法）和侵入性机械通气（ICTV），阐述了吸入一氧化氮（iNO）如何与先进的呼吸辅助性治疗相结合。在新生儿肺动脉高压领域，体外膜氧气疗法）和机械通气得到了进一步研究，凸显了新生儿科工作流程和设备相容性的重要性。依最终使用者划分，研究对象包括门诊手术中心、居家医疗、医院和专科诊所，每种环境对库存管理通讯协定、人员配备和供应合约模式的要求各不相同。按分销管道划分，研究对象透过直接竞标、分销合作伙伴和线上管道进行市场调查，这些管道在预期前置作业时间、合约结构以及产品随附的技术和临床支援程度方面存在差异。

综上所述，这种细分揭示了为什么产品选择和筹资策略不能一概而论地适用于所有医疗机构。营运多个加护病房的医院可能会优先选择整合监测和服务合约的呼吸机平台，而家庭护理计画则会倾向于选择配备清晰培训和远端监测支援的紧凑型气瓶解决方案。分销偏好也各不相同：对于寻求价格和服务保障的大型综合医疗服务网络而言，直接竞标通常是合适的选择；分销合作伙伴能够提供物流知识和覆盖区域系统的广泛产品渠道；而在线渠道则为小型诊所和门诊病人项目提供了快速补货的机会。这些细微差别要求製造商和供应商采取独特的商业性策略和量身定制的临床支援模式，以期在医疗保健领域获得长期应用。

美洲、中东和非洲以及亚太地区临床基础设施、采购惯例和法规的差异如何塑造差异化策略

在吸入式一氧化氮领域，临床应用、供应链配置和监管参与的优先事项持续受到区域动态的影响。美洲的医疗保健环境多样，从大型三级医疗中心到乡村医院，不一而足，因此，大型医院需要可扩展的发生器解决方案，而社区和居家医疗项目则需要可携式气瓶。在该地区，支付方结构和医疗服务提供者的采购惯例对合约策略和产品协议中包含的支持力度有显着影响。

欧洲、中东和非洲复杂的法律规范和供应模式有利于灵活应变的供应策略。在一些国家，集中采购和国家指南支援快速采用和标准化通讯协定，而在其他国家，分散的体系则为分销合作伙伴提供在地化服务和培训创造了机会。该全部区域重症加护能力和新生儿基础设施的差异，要求采用能够适应不同临床需求和医疗机构能力的灵活供应模式。

亚太地区的特点是成熟城市中心与新兴区域医院之间存在显着差异，同时基础设施投资迅速成长，临床通讯协定也不断发展。重症加护能力的提升和新生儿服务的扩展推动了对携带式和一体化医疗服务系统的需求。製造商和供应商若能使其产品设计与当地的监管要求、培训基础设施和物流实际情况相符，便能更好地支持医疗服务的可及性，同时充分利用三大区域不同的报销和采购环境。

竞争差异化概述：交付创新、卓越服务和策略性经销伙伴驱动供应商偏好和采购决策。

该领域的竞争格局反映了技术创新、差异化服务模式和策略通路伙伴关係的综合作用。领先的供应商正在投资于能够减少临床操作摩擦的交付平台，包括更简便的设定、更清晰的剂量控制以及支援文件记录和品质保证的整合监测。同时，各公司正透过售后服务模式实现差异化，这些模式包括维护合约、临床教育计画和远端支持，以确保持续运作并遵循最佳实践通讯协定。

与製造商和分销合作伙伴的伙伴关係已成为商业策略的基石，有助于扩大地域覆盖范围并提供可靠的物流支援。透过提供结构化培训、实证资料包和灵活的资金筹措方案来吸引临床相关人员的供应商，正逐渐获得大型医院系统和新生儿网路的青睐。儘管输送系统和专有气体配方相关的智慧财产权仍然重要，但在采购谈判中，临床支援、供应稳定性和设备易用性的综合作用正变得越来越关键。那些展现出强大服务能力并符合当地监管要求的新兴参与企业，可能会颠覆与传统供应商的关係，尤其是在基础设施投资加速发展的地区。

建议相关人员可以采取哪些行动来协调产品创新、供应弹性、临床支援和分销策略，以加快产品采用并减少部署摩擦。

产业领导者应采取整合策略，同时兼顾临床、营运和商业层面。首先，应优先投资于能够简化临床工作流程并确保在各种医疗环境中可靠运作的交付平台。其次，应建立健全的供应链弹性计划，包括多元化的采购管道、本地库存安排以及清晰的紧急应变计画，以减轻贸易中断和运输延误的影响。

第三，制定一套全面的临床支援方案，包括教育训练、实施指导和部署后监测，以向临床医生和采购团队展示其价值。第四，根据最终用户的特征调整分销和合约签订方式：为大型系统提供直接竞标，建立区域分销经销伙伴，并为门诊病人和小型医疗机构提供线上补货选项。最后，儘早与当地监管机构和报销相关人员接洽，明确准入途径，并使循证实践符合支付方的预期。透过结合这些步骤，企业可以减少部署阻力，增强临床信心，并在多元化的医疗保健环境中巩固商业性地位。

我们透明的调查方法结合了主要相关人员的访谈和二手临床及监管信息，以从临床和采购领域交叉验证见解。

本分析的调查方法融合了定性和定量方法，旨在从实证观点分析临床实践、采购趋势和产品部署。主要研究包括对临床医生、呼吸治疗师、采购人员和分销负责人进行结构化访谈，以收集有关设备易用性、供应链挑战和临床通讯协定整合的一线见解。二级资讯来源包括同行评审的临床文献、监管指导文件和已发布的临床实践标准，从而将对设备和应用的讨论建立在医学认可的证据基础之上。

数据综合重点在于跨资讯来源三角验证，以检验观察到的趋势并揭示不同应用情境（包括成人肺动脉高压、急性呼吸窘迫症候群和新生儿肺动脉高压）中采用驱动因素的差异。細項分析透过将产品形式、应用子类型、最终用户环境和分销管道映射到实际使用模式和购买行为来建构。对于证据仍在发展中或区域异质性限制了结果普遍适用性的情况，研究明确指出了其局限性和注意事项。该调查方法优先考虑透明度和可重复性，使读者能够追溯结论的来源，并了解临床和营运实际情况如何影响最终的见解。

结论强调以临床医生为中心的设计、供应弹性以及协作部署策略是持续获得吸入一氧化氮疗法的基础。

吸入一氧化氮（iNO）是多种严重呼吸道疾病治疗中不可或缺且用途广泛的辅助疗法，其有效应用取决于产品设计、临床通讯协定和给药策略与实际医疗环境的契合度。 iNO 的临床进展和给药创新正在拓展其应用范围和方式，而采购和监管动态也日益影响其可用性和运作准备。采用整合技术选择、临床医生培训和供应保障的整体方法的机构，将更有利于确保患者获得不间断的治疗，并充分发挥该治疗方法的临床益处。

展望未来，成功将取决于协作模式，将製造商、分销合作伙伴、临床团队和采购部门聚集在一起，共同打造适合各种医疗环境的解决方案。透过专注于易于整合、可验证的临床支援和灵活的分销机制，相关人员可以减少采用障碍，并确保在新生儿、成人和门诊护理中实现治疗目标。结论强调，协作、韧性和以临床医生为中心的设计是持续获得治疗和优化患者疗效的支柱。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 探讨吸入一氧化氮疗法治疗 COVID-19 诱发的急性呼吸窘迫症候群的临床试验取得进展
  • 携带式一氧化氮输送系统的出现，使得肺动脉高压的家庭管理成为可能。
  • 生技公司与设备製造商建立策略伙伴关係，以提高吸入一氧化氮（iNO）的输送效率
  • 下一代一氧化氮发生器的监管核准在于降低成本和提高可及性
  • 研究联合治疗抗病毒药物疗法和吸入一氧化氮疗法对改善呼吸道预后的作用

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 吸入式一氧化氮市场（依产品分类）

  • 圆柱
  • 发电机
  • 油船

9. 吸入式一氧化氮市场依应用领域划分

  • 成人肺动脉高压
    • 特发性
    • 次发性
  • ARDS
    • 体外膜氧气疗法
    • 侵入性通气
  • 新生儿肺动脉高压
    • 体外膜氧气疗法
    • 机械通气

10. 吸入式一氧化氮市场（依最终用户划分）

  • 门诊手术中心
  • 居家医疗
  • 医院
  • 专科诊所

11. 吸入式一氧化氮市场依分销管道划分

  • 直接竞标
  • 销售合作伙伴
  • 在线的

12. 各地区吸入式一氧化氮市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 吸入式一氧化氮市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国吸入式一氧化氮市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Mallinckrodt plc
    • Linde plc
    • Air Liquide SA
    • Air Products and Chemicals, Inc.
    • Messer SE & Co. KGaA
    • Nippon Sanso Holdings Corporation
    • Bellerophon Therapeutics, Inc.
    • GENERON IGS Inc.
Product Code: MRR-2D668742FD36

The Inhaled Nitric Oxide Market is projected to grow by USD 1,313.61 million at a CAGR of 6.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 821.09 million
Estimated Year [2025] USD 871.37 million
Forecast Year [2032] USD 1,313.61 million
CAGR (%) 6.04%

A comprehensive introduction to inhaled nitric oxide that frames its clinical role, delivery modalities, and strategic relevance across neonatal and adult pulmonary care settings

Inhaled nitric oxide (iNO) has evolved from a niche therapeutic into a critical adjunctive intervention across several acute and chronic pulmonary conditions. Its role as a selective pulmonary vasodilator with rapid onset and short half-life underpins its clinical utility in environments where rapid modulation of pulmonary vascular resistance and oxygenation are required. Clinicians and health system leaders increasingly view iNO as an essential tool for targeted respiratory support when conventional therapies are insufficient, driving interest from hospital administrators, respiratory therapy teams, and procurement functions alike.

As therapeutic pathways converge between neonatal intensive care, adult critical care, and specialized pulmonary programs, stakeholders are seeking deeper understanding of how product formats, delivery platforms, and distribution channels influence clinical workflows and operational readiness. This report centers on product-level differentiation across cylinder, generator, and tanker formats, and how these delivery modalities interact with application-specific protocols from neonatal pulmonary hypertension to acute respiratory distress management in adults. By integrating clinical, logistical, and payer-facing perspectives, the introduction underscores the product's clinical rationale, real-world deployment scenarios, and the strategic considerations that decision-makers must weigh when incorporating iNO into care pathways.

How technological advances, regulatory adjustments, and supply resilience initiatives are collectively reshaping clinical adoption and procurement strategies for inhaled nitric oxide

Recent years have produced several transformative shifts in the inhaled nitric oxide landscape that are reshaping clinical adoption and supply chain dynamics. Advances in delivery technology have enabled more compact, integrated generators and portable cylinder solutions, reducing bedside set-up times and expanding suitability for ambulatory and homecare contexts. Parallel to technological improvements, expanding clinical protocols and broader acceptance of iNO in refractory hypoxemia and pulmonary hypertension scenarios have shifted institutional procurement priorities toward reliable, on-demand supply models.

Regulatory and reimbursement developments have also influenced clinical decision-making, prompting providers to re-evaluate treatment algorithms and to invest in staff training and infrastructure. Strategic partnerships between clinical teams and distribution partners have emerged as a key mechanism to mitigate supply volatility and ensure continuity of care. In addition, a greater emphasis on interoperability and data integration has encouraged manufacturers to incorporate usage-tracking features into devices, supporting quality assurance and facilitating discussions with payers and health systems about appropriate utilization and protocols. Taken together, these shifts are creating a landscape in which clinical effectiveness, delivery flexibility, and supply resilience are increasingly interdependent.

Assessing the operational and procurement consequences of U.S. tariff changes in 2025 that prompted sourcing shifts and supply chain resilience planning for inhaled nitric oxide

The introduction of tariff changes in the United States in 2025 created a complex ripple effect across procurement, pricing structures, and supply chain planning for inhaled nitric oxide products and associated hardware. Import duties and customs adjustments increased the cost of certain imported components and finished delivery systems, prompting manufacturers and distributors to reassess sourcing strategies and inventory practices. This environment encouraged accelerated nearshoring of key manufacturing steps where feasible, as well as renegotiation of supply agreements to accommodate altered landed costs and lead times.

Hospitals and health systems responded by intensifying collaboration with distribution partners to secure longer-term supply contracts and contingency provisions. Clinical teams incorporated supply risk assessments into therapy selection discussions, prioritizing devices and formats that could be supported reliably under altered trade conditions. At the same time, purchasers considered total cost of ownership across cylinder, generator, and tanker options, factoring in inventory holding, transportation constraints, and training requirements. These strategic adaptations reduced exposure to isolated tariff-driven disruptions and enhanced continuity of care, while highlighting the importance of flexible contracting, multi-supply sourcing, and inventory visibility in maintaining access to critical inhaled nitric oxide therapies.

Detailed segmentation-driven insights explaining how product formats, clinical applications, end-user environments, and distribution channels determine procurement and clinical deployment choices

Segmentation analysis reveals critical distinctions in product choice, clinical application, end-user preferences, and distribution pathways that together inform adoption and operational planning. Based on Product, the market is studied across Cylinder, Generator, and Tanker, and each format brings unique implications for storage, bedside workflow, and maintenance requirements; cylinders support rapid deployment and smaller institutions, generators enable integrated dosing controls suited to high-volume centers, and tankers are optimal for centralized supply models serving multiple facilities. Based on Application, the market is studied across Adult Pulmonary Hypertension, ARDS, and Neonatal Pulmonary Hypertension. The Adult Pulmonary Hypertension segment is further studied across Idiopathic and Secondary, reflecting divergent diagnostic pathways, comorbidity profiles, and long-term management strategies. The ARDS segment is further studied across Extracorporeal Membrane Oxygenation and Invasive Ventilation, illustrating how iNO integrates with advanced respiratory support modalities. The Neonatal Pulmonary Hypertension segment is further studied across Extracorporeal Membrane Oxygenation and Mechanical Ventilation, underscoring the specialized neonatal workflows and device compatibility needs. Based on End User, the market is studied across Ambulatory Surgical Centers, Homecare, Hospitals, and Specialty Clinics, with each setting demanding different inventory protocols, staff competencies, and contractual models for supply. Based on Distribution Channel, the market is studied across Direct Tender, Distribution Partner, and Online, and these channels differ in lead time expectations, contract structure, and the degree of technical and clinical support bundled with the product.

Taken together, segmentation clarifies why product selection and procurement strategies cannot be generalized across all care settings. A hospital operating multiple intensive care units will prioritize generator platforms with integrated monitoring and service agreements, whereas homecare programs will prefer compact cylinder solutions with clear training and telemonitoring support. Distribution preferences also vary: direct tenders often suit large integrated delivery networks seeking price and service guarantees, distribution partners provide logistics expertise and breadth of product access for regional systems, and online channels create opportunities for rapid replenishment for smaller clinics and outpatient programs. These nuances demand distinct commercial approaches and tailored clinical support models for manufacturers and suppliers seeking durable adoption across the care continuum.

How regional clinical infrastructure, procurement practices, and regulatory diversity shape differentiated strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape priorities for clinical adoption, supply chain configuration, and regulatory engagement within the inhaled nitric oxide landscape. The Americas feature a diverse set of care settings ranging from large tertiary centers to rural hospitals, prompting a dual emphasis on scalable generator solutions for high-volume hospitals and portable cylinder options for community and homecare programs. In this region, payer structures and institutional procurement practices strongly influence contracting strategies and the degree of support bundled with product agreements.

Europe, Middle East & Africa present a complex tapestry of regulatory frameworks and delivery models that favor adaptable supply strategies. In some countries centralized procurement and national guidelines drive rapid uptake and standardized protocols, while in others fragmented systems create opportunity for distribution partners to deliver localized service and training. Differences in critical care capacity and neonatal care infrastructure across this combined region necessitate flexible delivery formats that can be adapted to varied clinical needs and facility capabilities.

Asia-Pacific remains a region of rapid infrastructure investment and evolving clinical protocols, with significant heterogeneity between mature urban centers and emerging regional hospitals. Growing critical care capacity and expanding neonatal services are increasing demand for both portable and integrated delivery systems. Manufacturers and suppliers that align product design with local regulatory requirements, training infrastructure, and logistical realities are positioned to support improved access while navigating diverse reimbursement and procurement environments across the three major regions.

An overview of competitive differentiation where delivery innovation, service excellence, and strategic distribution partnerships drive supplier preference and procurement decisions

Competitive dynamics in this sector reflect a combination of technological innovation, service model differentiation, and strategic channel partnerships. Leading providers are investing in delivery platforms that reduce clinical friction-simpler setup, clearer dosing controls, and integrated monitoring that supports documentation and quality assurance. At the same time, companies are differentiating through after-sales service models that include maintenance contracts, clinical education programs, and remote support to ensure continuous operation and adherence to best-practice protocols.

Partnerships between manufacturers and distribution partners have become a cornerstone of commercial strategy, enabling broader geographic reach and more reliable logistics support. Suppliers that align with clinical stakeholders by offering structured training, evidence packages, and adaptable financing options gain preferred status with major hospital systems and neonatal networks. Intellectual property around delivery systems and proprietary gas formulations remains important, but the combination of clinical support, supply resilience, and device usability is increasingly decisive in procurement discussions. New entrants that demonstrate strong service capabilities and compliance with regional regulatory requirements can disrupt traditional supplier relationships, particularly in regions where infrastructure investment is accelerating.

Actionable recommendations for stakeholders to align product innovation, supply resilience, clinical support, and distribution strategies to accelerate adoption and reduce deployment friction

Industry leaders should pursue an integrated strategy that addresses clinical, operational, and commercial dimensions simultaneously. First, prioritize investment in delivery platforms that simplify clinical workflows and enable reliable performance across diverse care settings; ease of use and interoperability with monitoring systems reduce training burdens and lower the threshold for broader adoption. Second, establish robust supply resilience plans, including diversified sourcing, local stocking agreements, and clear contingency protocols to mitigate the impact of trade disruptions and transportation delays.

Third, develop comprehensive clinical support packages that include education, implementation guidance, and post-deployment monitoring to demonstrate value to clinicians and procurement teams. Fourth, tailor distribution and contracting approaches to end-user profiles: direct tenders for large systems, distribution partnerships for regional coverage, and online replenishment options for outpatient and smaller facilities. Finally, engage with regional regulatory and reimbursement stakeholders early to clarify access pathways and to align evidence generation with payer expectations. These steps, taken together, help organizations reduce deployment friction, increase clinical confidence, and strengthen commercial positioning across heterogeneous healthcare environments.

A transparent methodology combining primary stakeholder interviews and secondary clinical and regulatory sources to triangulate insights across clinical and procurement domains

The research methodology underpinning this analysis integrated qualitative and quantitative approaches to produce an evidence-informed perspective on clinical practice, procurement trends, and product deployment. Primary research involved structured interviews with clinicians, respiratory therapists, procurement officers, and distribution executives to capture frontline insights into device usability, supply chain challenges, and clinical protocol integration. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and published clinical practice standards to ground device and application discussions in accepted medical evidence.

Data synthesis emphasized triangulation across sources to validate observed trends and to illuminate differences in adoption drivers across applications such as adult pulmonary hypertension, ARDS, and neonatal pulmonary hypertension. Segmentation analysis was constructed by mapping product formats, application subtypes, end-user environments, and distribution channels to real-world usage patterns and procurement behaviors. Limitations and caveats were explicitly noted where evidence was evolving or where regional heterogeneity constrained generalization. The methodology prioritizes transparency and reproducibility so that readers can trace conclusions back to source inputs and understand how clinical and operational realities informed final insights.

Conclusions emphasizing clinician-centered design, supply resilience, and collaborative deployment strategies as the foundation for sustained access to inhaled nitric oxide therapies

Inhaled nitric oxide remains an essential and versatile adjunct in the management of several severe respiratory conditions, and its effective deployment depends on aligning product design, clinical protocols, and supply strategies with the realities of care environments. Clinical advances and delivery innovation are expanding where and how iNO can be used, while procurement and regulatory dynamics increasingly shape accessibility and operational readiness. Organizations that adopt a holistic approach-one that integrates technology selection, clinician training, and supply resilience-are better positioned to maintain uninterrupted patient access and to realize the full clinical benefit of this therapy.

Looking ahead, success will hinge on collaborative models that bring together manufacturers, distribution partners, clinical teams, and procurement functions to create tailored solutions for each care setting. By focusing on ease of integration, demonstrable clinical support, and adaptable distribution mechanisms, stakeholders can reduce barriers to adoption and ensure that therapeutic objectives are met across neonatal, adult, and ambulatory care contexts. The conclusions emphasize alignment, resilience, and clinician-centered design as the pillars of sustained access and optimized patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical trial advances exploring inhaled nitric oxide therapy for COVID-19 induced acute respiratory distress syndrome
  • 5.2. Emergence of portable nitric oxide delivery systems enabling at home pulmonary hypertension management
  • 5.3. Strategic partnerships between biotech firms and device manufacturers to enhance iNO delivery efficiency
  • 5.4. Regulatory approvals for next generation nitric oxide generators focusing on cost reduction and accessibility
  • 5.5. Research into combination therapies coupling inhaled nitric oxide with antiviral agents for enhanced respiratory outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inhaled Nitric Oxide Market, by Product

  • 8.1. Cylinder
  • 8.2. Generator
  • 8.3. Tanker

9. Inhaled Nitric Oxide Market, by Application

  • 9.1. Adult Pulmonary Hypertension
    • 9.1.1. Idiopathic
    • 9.1.2. Secondary
  • 9.2. Ards
    • 9.2.1. Extracorporeal Membrane Oxygenation
    • 9.2.2. Invasive Ventilation
  • 9.3. Neonatal Pulmonary Hypertension
    • 9.3.1. Extracorporeal Membrane Oxygenation
    • 9.3.2. Mechanical Ventilation

10. Inhaled Nitric Oxide Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Inhaled Nitric Oxide Market, by Distribution Channel

  • 11.1. Direct Tender
  • 11.2. Distribution Partner
  • 11.3. Online

12. Inhaled Nitric Oxide Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Inhaled Nitric Oxide Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Inhaled Nitric Oxide Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Mallinckrodt plc
    • 15.3.2. Linde plc
    • 15.3.3. Air Liquide S.A.
    • 15.3.4. Air Products and Chemicals, Inc.
    • 15.3.5. Messer SE & Co. KGaA
    • 15.3.6. Nippon Sanso Holdings Corporation
    • 15.3.7. Bellerophon Therapeutics, Inc.
    • 15.3.8. GENERON IGS Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. INHALED NITRIC OXIDE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. INHALED NITRIC OXIDE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INHALED NITRIC OXIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 284. GCC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 285. GCC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. GCC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 288. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 289. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 290. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 291. GCC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 292. GCC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 293. GCC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. GCC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. GCC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. GCC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2025-2032 (USD MILLION)
  • TABLE 321. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2024 (USD MILLION)
  • TABLE 322. BRICS IN